The Future of Cervical Cancer Screening: HPV Extended Genotyping, Risk Stratification, and Beyond
Sponsored by BD Life Sciences/Omnia Education
Wednesday, April 5
12:00 PM to 1:30 PM
Regency Ballroom U
Lunch will be served to all participants of the symposium
Cervical cancer screening (CCS) continues to be an area of not only critical clinical discussion, but also one of emerging technology. Join us as Mark H. Stoler, MD, addresses the potential value of incorporating HPV extended genotyping into CCS and triage; and Jesper Bonde, PhD, Dipl Med Sci, discusses how novel technology platforms such as self-sampling, urine sampling, and computer-analyzed cytology can effectively expand CCS coverage while simultaneously improving diagnostic precision.